美国心脏病学会(ACC)于近期发布了“2022 ACC专家共识决策路径:降低低密度脂蛋白胆固醇的非他汀类治疗在动脉粥样硬化性心血管疾病风险管理中的作用”(2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Diseas...
美国心脏病学会(ACC)于近期发布了“2022 ACC专家共识决策路径:降低低密度脂蛋白胆固醇的非他汀类治疗在动脉粥样硬化性心血管疾病风险管理中的作用”(2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Diseas...
美国心脏病学会(ACC)于近期发布了“2022 ACC专家共识决策路径:降低低密度脂蛋白胆固醇的非他汀类治疗在动脉粥样硬化性心血管疾病风险管理中的作用”(2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for L...
美国心脏病学会(ACC)于近期发布了“2022 ACC专家共识决策路径:降低低密度脂蛋白胆固醇的非他汀类治疗在动脉粥样硬化性心血管疾病风险管理中的作用”(2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for L...
文献索引:Writing Committee, Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology So...
To this end, the ACC has shiftedeveloping isolated documents to creating inte-“solution sets.” These are groups of closely relatedmember needs.3Expert Consensus Decision Pathways represent a keycomponent of solution sets. Standard methodology fordeveloping an Expert Consensus Decision Pathway is as...
3. Maddox TM, Januzzi JL, Allen LA, et al.2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Overs...
2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2021;77:772...
2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation[J]. J Am Coll Cardiol,2017,69(7):871-898. [36] BIRNIE D H,HEALEY J S,WELLS G A,et al. Pacemaker or defibrillator surgery without interruption of ...
After nearly a decade of development, the leadless pacemaker has entered a period of rapid growth. Based on the current clinical application experience, evidence-based research, and updated guidelines, combined with the "Chinese expert consensus on leadless pacemakers (2022)," this operating procedure...